The first days of the new year witnessed multinationals including Novartis AG tie up with developers of small interfering RNA therapies from China, once regarded as a backwater for R&D into such a novel drug modality. (Also see "Asia Deal Watch: Argo Partners RNAi Programs With Novartis In Major Biobucks Pact" - Scrip, 8 January, 2024.) (Also see "BI Gets Down To Business Early With Trio Of Pacts" - Scrip, 5 January, 2024.)
Key Takeaways
-
Sirius Therapeutics, a Chinese developer of siRNA therapies, is taking aim at cardiovascular diseases with a potential once-yearly treatment regimen.
Sirius Therapeutics, one of the emerging Chinese siRNA-focused contenders, has also been in the foreground in the race to globalize...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?